CYP19A1 and breast cancer: From the results obtained and by comparison with our previously reported related compounds based on the phenstatin scaffold [65], the 1,2,4-triazole-containing chalcone-based compound 22b was identified as a potential dual-acting drug for the treatment of breast cancer targeting both aromatase inhibition and tubulin polymerization.